Our top pick for
This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.
Alector, Inc is a biotechnology business based in the US. Alector shares (ALEC) are listed on the NASDAQ and all prices are listed in US Dollars. Alector employs 153 staff and has a trailing 12-month revenue of around USD$19 million.
|Latest market close||USD$12.73|
|52-week range||USD$9.35 - USD$35.93|
|50-day moving average||USD$11.6566|
|200-day moving average||USD$20.7446|
|Wall St. target price||USD$34.88|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.255|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-25)||-4.21%|
|1 month (2020-11-06)||11.96%|
|3 months (2020-09-04)||2.58%|
|6 months (2020-06-05)||-57.55%|
|1 year (2019-12-05)||-34.35%|
|2 years (2018-12-02)||N/A|
|3 years (2017-12-02)||N/A|
|5 years (2015-12-02)||N/A|
|Revenue TTM||USD$19 million|
|Gross profit TTM||USD$-79,309,000|
|Return on assets TTM||-18.48%|
|Return on equity TTM||-49.12%|
|Market capitalisation||USD$745.5 million|
TTM: trailing 12 months
There are currently 10.7 million Alector shares held short by investors – that's known as Alector's "short interest". This figure is 26.6% up from 8.4 million last month.
There are a few different ways that this level of interest in shorting Alector shares can be evaluated.
Alector's "short interest ratio" (SIR) is the quantity of Alector shares currently shorted divided by the average quantity of Alector shares traded daily (recently around 938539.13808267). Alector's SIR currently stands at 11.37. In other words for every 100,000 Alector shares traded daily on the market, roughly 11370 shares are currently held short.
However Alector's short interest can also be evaluated against the total number of Alector shares, or, against the total number of tradable Alector shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Alector's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 Alector shares in existence, roughly 130 shares are currently held short) or 0.2341% of the tradable shares (for every 100,000 tradable Alector shares, roughly 234 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Alector.
Find out more about how you can short Alector stock.
We're not expecting Alector to pay a dividend over the next 12 months.
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in phase II clinical trial for the treatment of frontotemporal dementia disease; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002 and AL003, which are in phase 1b clinical trial for the treatment of Alzheimer's disease. In addition, it has 10 programs under research and development stage. The company has a collaboration agreement with Adimab, LLC for the research and development of antibodies. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.
Everything we know about the Loha Co. IPO, plus information on how to buy in.
Everything we know about the Stem Inc IPO, plus information on how to buy in.
Everything we know about the View Inc IPO, plus information on how to buy in.
Everything we know about the Chime IPO, plus information on how to buy in.
Steps to owning and managing WPRT, with 24-hour and historical pricing before you buy.
Steps to owning and managing WBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing WLK, with 24-hour and historical pricing before you buy.
Steps to owning and managing WDC, with 24-hour and historical pricing before you buy.
Steps to owning and managing WAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing VSAT, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.